[go: up one dir, main page]

CL2017000711A1 - Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos. - Google Patents

Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos.

Info

Publication number
CL2017000711A1
CL2017000711A1 CL2017000711A CL2017000711A CL2017000711A1 CL 2017000711 A1 CL2017000711 A1 CL 2017000711A1 CL 2017000711 A CL2017000711 A CL 2017000711A CL 2017000711 A CL2017000711 A CL 2017000711A CL 2017000711 A1 CL2017000711 A1 CL 2017000711A1
Authority
CL
Chile
Prior art keywords
bind
bispecific monovalent
monovalent diabodies
diabodies
bispecific
Prior art date
Application number
CL2017000711A
Other languages
English (en)
Inventor
Leslie S Johnson
Ezio Bonvini
Paul A Moore
Chia Ying Kao Lam
Liqin Liu
Scott Koenig
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of CL2017000711A1 publication Critical patent/CL2017000711A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epoxy Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Furan Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

<p>LOS DIACUERPOS MONOVALENTES BI-ESPECIFICOS CD19 X CD3, Y PARTICULARMENTE, ANTICUERPOS FC MONOVALENTES BI-ESPECÍFICOS CD19 X CD3, SON CAPACES DE UNIRSE SIMULTÁNEAMENTE A CD19 Y CD3, Y SE UTILIZAN EN EL TRATAMIENTO DE NEOPLASIAS HEMATOLÓGICAS.</p>
CL2017000711A 2014-09-26 2017-03-24 Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos. CL2017000711A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462055695P 2014-09-26 2014-09-26

Publications (1)

Publication Number Publication Date
CL2017000711A1 true CL2017000711A1 (es) 2017-12-15

Family

ID=55581876

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000711A CL2017000711A1 (es) 2014-09-26 2017-03-24 Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos.

Country Status (29)

Country Link
US (3) US10633443B2 (es)
EP (1) EP3197917B1 (es)
JP (1) JP6839075B2 (es)
KR (1) KR20170063755A (es)
CN (1) CN107484416A (es)
AP (1) AP2017009823A0 (es)
AR (1) AR101997A1 (es)
AU (1) AU2015321546B2 (es)
CA (1) CA2962603A1 (es)
CL (1) CL2017000711A1 (es)
CO (1) CO2017002793A2 (es)
CR (1) CR20170109A (es)
CU (1) CU20170041A7 (es)
DO (1) DOP2017000083A (es)
EA (1) EA201790719A1 (es)
ES (1) ES2935062T3 (es)
IL (1) IL251377B (es)
MA (1) MA40573A (es)
MD (1) MD20170040A2 (es)
MX (1) MX375669B (es)
NI (1) NI201700037A (es)
PE (1) PE20170894A1 (es)
PH (1) PH12017500544A1 (es)
SG (1) SG11201702310QA (es)
TN (1) TN2017000106A1 (es)
TW (1) TWI706960B (es)
UY (1) UY36316A (es)
WO (1) WO2016048938A1 (es)
ZA (1) ZA201701985B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
SG11201702310QA (en) * 2014-09-26 2017-04-27 Macrogenics Inc Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
AU2015323860B2 (en) 2014-09-29 2021-05-27 Duke University Bispecific molecules comprising an HIV-1 envelope targeting arm
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
AR107781A1 (es) 2015-12-14 2018-06-06 Macrogenics Inc Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
SG11201907753TA (en) 2017-02-24 2019-09-27 Macrogenics Inc Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201912774RA (en) 2017-06-20 2020-01-30 Teneobio Inc Anti-bcma heavy chain-only antibodies
EP3684817A4 (en) * 2017-09-22 2021-06-09 Wuxi Biologics Ireland Limited. NEW BIS SPECIFIC CD3 / CD19 POLYPEPTIDE COMPLEXES
MA50188A (fr) 2017-09-22 2021-06-02 Wuxi Biologics Ireland Ltd Nouveaux complexes polypeptidiques bispécifiques
MA50670A (fr) * 2017-09-29 2020-08-05 Janssen Biotech Inc Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose
CN109706163A (zh) * 2017-10-26 2019-05-03 深圳新诺微环生物科技有限公司 微环dna表达连接人与动物靶细胞与效应细胞的桥接分子及其应用
CN109957026A (zh) * 2017-12-22 2019-07-02 成都恩沐生物科技有限公司 共价多特异性抗体
CA3089877A1 (en) 2018-02-15 2019-08-22 Macrogenics, Inc. Variant cd3-binding domains and their use in combination therapies for the treatment of disease
WO2020018922A1 (en) 2018-07-20 2020-01-23 Teneobio, Inc. Heavy chain antibodies binding to cd19
CN109402168A (zh) * 2018-10-30 2019-03-01 深圳新诺微环生物科技有限公司 微环dna表达连接her2阳性细胞与效应细胞的桥接分子及其应用
WO2020088164A1 (zh) * 2018-11-01 2020-05-07 山东新时代药业有限公司 双特异性抗体及其用途
WO2020052692A2 (en) * 2018-12-04 2020-03-19 Novartis Ag Binding molecules against cd3 and uses thereof
JP2022525435A (ja) * 2019-04-08 2022-05-13 メモリアル スローン ケタリング キャンサー センター Ｃｄ１９抗体およびこれを使用する方法
KR20220010544A (ko) 2019-05-21 2022-01-25 노파르티스 아게 Cd19 결합 분자 및 이의 용도
CN112111012B (zh) * 2019-06-20 2023-07-04 成都恩沐生物科技有限公司 共价多特异性抗体
WO2022165171A1 (en) 2021-01-28 2022-08-04 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
CN113488112A (zh) * 2021-06-10 2021-10-08 五邑大学 一种共价结合预测方法及装置
EP4507790A1 (en) 2022-04-11 2025-02-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
US20240277844A1 (en) 2023-02-17 2024-08-22 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0092918B1 (en) 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
AU6290090A (en) 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
EP0550436A1 (en) 1989-11-06 1993-07-14 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
DE69232706T2 (de) 1991-05-01 2002-11-28 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Rockville Verfahren zur behandlung infektiöser respiratorischer erkrankungen
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
AU2605592A (en) 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
CA2207961A1 (en) 1995-01-05 1996-07-11 Robert J. Levy Surface-modified nanoparticles and method of making and using same
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5916597A (en) 1995-08-31 1999-06-29 Alkermes Controlled Therapeutics, Inc. Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
WO1997032572A2 (en) 1996-03-04 1997-09-12 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
ATE287257T1 (de) 1997-01-16 2005-02-15 Massachusetts Inst Technology Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
ES2198922T3 (es) 1998-06-24 2004-02-01 Advanced Inhalation Research, Inc. Particulas porosas grandes emitadas por un inhalador.
WO2002002781A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
US6992234B2 (en) 2000-11-06 2006-01-31 The Jackson Laboratory FcRn-based therapeutics for the treatment of auto-immune disorders
ITRM20010408A1 (it) 2001-07-10 2003-01-10 Univ Napoli Federico Ii Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
EP1293514B1 (en) 2001-09-14 2006-11-29 Affimed Therapeutics AG Multimeric single chain tandem Fv-antibodies
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
CA2605024C (en) 2005-04-15 2018-05-22 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
SG153825A1 (en) 2005-12-16 2009-07-29 Ibc Pharmaceuticals Inc Multivalent immunoglobulin-based bioactive assemblies
CA2654317A1 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
ES2399075T3 (es) 2006-08-30 2013-03-25 Genentech, Inc. Anticuerpos multiespecíficos
CN107226864A (zh) 2007-06-21 2017-10-03 宏观基因有限公司 共价双抗体及其用途
JP5727786B2 (ja) 2007-10-19 2015-06-03 シアトル ジェネティクス，インコーポレーテッド Ｃｄ１９結合性物質およびその使用
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
WO2010028795A1 (en) 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
WO2010028797A1 (en) 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
WO2010028796A1 (en) 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Trispecific hexavalent antibodies
SI2786762T1 (sl) 2008-12-19 2019-07-31 Macrogenics, Inc. Kovalentna diatelesa in njihove uporabe
KR20130080871A (ko) 2009-03-20 2013-07-15 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
BRPI1007602A2 (pt) 2009-05-27 2016-02-16 Hoffmann La Roche "anticorpo tri ou tetraespecífico, método para preparação de um anticorpo triespecífico ou tetraespecífico, célula hospedeira, composição, composição farmacêutica e método para o tratamento de um paciente com necessidade de terapia"
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
CA2787074A1 (en) * 2010-01-19 2011-07-28 Immunomedics, Inc. Novel antibodies that target the insulin-like growth factor type i receptor (igf-1r)
US20110206672A1 (en) 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
CN102946906B (zh) 2010-04-23 2015-07-15 弗·哈夫曼-拉罗切有限公司 生产异源多聚体蛋白质
SG187682A1 (en) 2010-08-02 2013-03-28 Macrogenics Inc Covalent diabodies and uses thereof
EP2709655B1 (en) 2011-05-17 2018-11-14 Trion Research GmbH Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
HUE044209T2 (hu) 2011-05-21 2019-10-28 Macrogenics Inc Humán és nem humán CD3-hoz kötõdni képes CD3-kötõ molekulák
EA201391753A1 (ru) * 2011-05-21 2014-08-29 Макродженикс, Инк. Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке
WO2012162583A1 (en) 2011-05-26 2012-11-29 Ibc Pharmaceuticals, Inc. Design and construction of novel multivalent antibodies
WO2013003647A2 (en) 2011-06-28 2013-01-03 Sea Lane Biotechnologies, Llc Multispecific stacked variable domain binding proteins
US20140155581A1 (en) 2011-07-06 2014-06-05 Medimmune, Llc Methods For Making Multimeric Polypeptides
KR102143506B1 (ko) * 2011-08-17 2020-08-12 글락소 그룹 리미티드 변형된 단백질 및 펩티드
EP2812432B1 (en) 2012-02-10 2020-10-14 Research Corporation Technologies, Inc. Fusion proteins comprising immunoglobulin constant domain-derived scaffolds
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
RU2014149681A (ru) 2012-05-24 2016-07-20 Ф. Хоффманн-Ля Рош Аг Антитела с множественной специфичностью
RU2650868C2 (ru) * 2012-07-13 2018-04-17 Займворкс Инк. Биспецифические асимметричные гетеродимеры, содержащие анти-cd3 конструкции
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
US9915665B2 (en) 2012-12-28 2018-03-13 Abbvie Inc. High-throughput system and method for identifying antibodies having specific antigen binding activities
DK2943511T3 (da) 2013-01-14 2019-10-21 Xencor Inc Nye heterodimeriske proteiner
KR102561553B1 (ko) * 2013-03-15 2023-07-31 젠코어 인코포레이티드 이형이량체 단백질
US11384149B2 (en) * 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk) * 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EA035419B9 (ru) * 2014-05-29 2020-08-07 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы и способы их применения
TWI693232B (zh) * 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
SG11201702310QA (en) * 2014-09-26 2017-04-27 Macrogenics Inc Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
AU2015323860B2 (en) * 2014-09-29 2021-05-27 Duke University Bispecific molecules comprising an HIV-1 envelope targeting arm
AU2015380455A1 (en) * 2015-01-26 2017-08-03 Macrogenics, Inc. Multivalent molecules comprising DR5-binding domains
CA2995709A1 (en) * 2015-08-17 2017-02-23 Macrogenics,Inc. Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof
AR106935A1 (es) * 2015-12-04 2018-03-07 Macrogenics Inc Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos
EP3448427A1 (en) * 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
RU2022101891A (ru) * 2016-06-07 2022-02-07 Мэкроудженикс, Инк. Способы применения cd32b x cd79b-связывающих молекул при лечении воспалительных заболеваний и расстройств
SG11201907753TA (en) * 2017-02-24 2019-09-27 Macrogenics Inc Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
WO2019118266A1 (en) * 2017-12-12 2019-06-20 Macrogenics Inc. Bispecific cd 16-binding molecules and their use in the treatment of disease
CA3089877A1 (en) * 2018-02-15 2019-08-22 Macrogenics, Inc. Variant cd3-binding domains and their use in combination therapies for the treatment of disease
US20210246194A1 (en) * 2018-05-18 2021-08-12 Macrogenics, Inc. Optimized gp41-Binding Molecules and Uses Thereof

Also Published As

Publication number Publication date
US10633443B2 (en) 2020-04-28
AP2017009823A0 (en) 2017-03-31
ZA201701985B (en) 2018-05-30
AU2015321546B2 (en) 2020-09-03
KR20170063755A (ko) 2017-06-08
MX2017003784A (es) 2017-06-28
NZ730348A (en) 2024-03-22
IL251377B (en) 2021-03-25
NI201700037A (es) 2017-07-18
TW201617369A (zh) 2016-05-16
SG11201702310QA (en) 2017-04-27
TWI706960B (zh) 2020-10-11
US20170247452A1 (en) 2017-08-31
PH12017500544A1 (en) 2017-08-07
WO2016048938A1 (en) 2016-03-31
ES2935062T3 (es) 2023-03-01
US20230399399A1 (en) 2023-12-14
EA201790719A1 (ru) 2017-07-31
JP6839075B2 (ja) 2021-03-03
JP2017533891A (ja) 2017-11-16
CU20170041A7 (es) 2017-09-06
EP3197917A1 (en) 2017-08-02
IL251377A0 (en) 2017-05-29
UY36316A (es) 2016-04-29
CO2017002793A2 (es) 2017-06-20
CA2962603A1 (en) 2016-03-31
CR20170109A (es) 2017-07-26
MA40573A (fr) 2016-03-31
US11639386B2 (en) 2023-05-02
AR101997A1 (es) 2017-01-25
MD20170040A2 (ro) 2017-07-31
EP3197917B1 (en) 2022-10-12
EP3197917A4 (en) 2018-06-27
DOP2017000083A (es) 2017-04-30
MX375669B (es) 2025-03-06
TN2017000106A1 (en) 2018-07-04
PE20170894A1 (es) 2017-07-12
US20200216537A1 (en) 2020-07-09
BR112017005988A2 (pt) 2017-12-19
AU2015321546A1 (en) 2017-04-13
CN107484416A (zh) 2017-12-15

Similar Documents

Publication Publication Date Title
CL2017000711A1 (es) Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos.
CY1124993T1 (el) Ετεροδιμερικα αντισωματα που δεσμευουν cd3 και cd20
CL2017002752A1 (es) Anticuerpos heterodiméricos que unen anticuerpos cd3 y tumorales
CL2017001361A1 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
MX2015017487A (es) Anticuerpos cd3 humanizados o quimericos.
PL3328889T3 (pl) Konstrukty przeciwciała dwuswoistego wiążące DLL3 i CD3
IL253166B (en) Bispecific antibodies against cd3 and cd20
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
RS60916B1 (sr) Anti-cd3 antitela, anti-cd123 antitela i bispecifična antitela koja se specifično vezuju za cd3 i/ili cd123
CL2016002460A1 (es) Anticuerpos biespecíficos que se unen a cd38 y cd3
PE20160509A1 (es) Diacuerpos monovalentes biespecificos que son capaces de unir cd123 y cd3, y usos de los mismos
LT3283524T (lt) Bispecifiniai antikūnų konstruktai, skirti cdh3 ir cd3
HUE054384T2 (hu) EGFRVIII-T és CD3-at kötõ bispecifikus antitest-konstrukciók
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
BR112016000666A2 (pt) Constructos de ligação de antígeno cd3 e cd19 biespecíficos
MX2016009050A (es) Construcciones biespecificas de union a los antigenos cd3 y cd19.
EA201691473A1 (ru) Биспецифические анти-il-13/il-17 антитела и их применение
AR105714A1 (es) Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
TH1601000737A (th) ไบสเปซิฟิกโมโนวาเลนท์ไดอะบอดีย์ ที่มีความสามารถของการเชื่อมต่อกับ gpa33 และ cd3, และการใช้ของสิ่งเหล่านั้น
TH1601003592A (th) แอนติบอดีต่อต้าน cd3 และวิธีการใช้
TH1601000783A (th) ไบ-สเปซิฟิกโมโนวาเลนต์ไดอะบอดี้ที่สามารถจับ cd123 และ cd3, และการใช้ของมัน